OCRA runs one grant cycle each year. Requests for Proposals (RFPs) are issued every spring. We use a two step application and peer review process. Letters of Intent (LOIs) are due in early spring and undergo a rigorous peer review by our Scientific Advisory Committee. After LOI review, a subset of those applicants are invited to submit full proposals. Final grant notifications are made in the fall. (This timeline is subject to change.)
The review process—including all meeting deliberations, scores and written critiques of proposals, as well as other materials provided for the review of proposals—is confidential. A confidentiality and conflict-of-interest statement must be signed by each reviewer. Grants for projects selected through this process are then made to non-profit medical institutions on behalf of individual investigators or project directors.
Have questions about OCRA’s grant cycle and programs? View our FAQs.
2024 Health Equity Research Grant, Sponsored by GSK: Timeline
|Letter of Intent (LOI) Opens||July 25, 2023||Passed|
|Letter of Intent (LOI) Due||August 22, 2023||Passed|
|Letter of Intent Decisions/Full Proposal Opens||Late September 2023||Passed|
|Full Proposal Due||October 26, 2023||Next|
|Funding Notification||Mid-December 2023|
OCRA’s 2024 Grant Cycle
|Letter of Intent (LOI) Opens||March 1, 2023||Passed|
|Letter of Intent (LOI) Due||March 29, 2023||Passed|
|Letter of Intent Decisions/Full Proposal Opens||Early May 2023||Passed|
|Full Proposal Due||June 7, 2023||Passed|
|Funding Notification||End of September 2023||Next|
2024 Requests for Proposals
Please click on the links below to view the full RFPs for the four funding opportunities for OCRA’s 2024 grant cycle.
To apply to any of OCRA’s Grants, please apply through SmartSimple.
*all LOIs and Full Proposals MUST be submitted through SmartSimple. Extensions and late submissions will not be permitted.
If you would like to be added to our mailing list so you know when RFPs are available for future grant cycles, please send an email to email@example.com.